Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2012 Earnings Results

Arrowhead Pharmaceuticals Misses on EPS, Stock Down 14.15%

The earnings report indicates ongoing challenges for Arrowhead Pharmaceuticals, as evidenced by the missed EPS. The stock's significant drop of 14.15% reflects investor concerns about the company's performance and lack of guidance. Without clear direction from management, investors may remain cautious moving forward.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.71	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management acknowledged the difficulties faced in the quarter. They emphasized a long-term vision but did not offer specific guidance.

Management did not provide specific guidance for future quarters.

The company is focusing on long-term strategies despite current challenges.

Arrowhead Pharmaceuticals Misses on EPS, Stock Down 14.15%

Key numbers

Management commentary

Arrowhead Pharmaceuticals, Inc.

More earnings this week

Arrowhead Pharmaceuticals Misses on EPS, Stock Down 14.15%

Key numbers

Management commentary